Base Prospectus. The preliminary prospectus supplement dated July 22, 2020, relating to the offering of the Shares, including all documents incorporated therein by reference, filed with the Commission pursuant to General Instruction II.L of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the “U.S.
Appears in 1 contract
Sources: Underwriting Agreement (Aurinia Pharmaceuticals Inc.)
Base Prospectus. The preliminary prospectus supplement dated July 22March 13, 20202017, relating to the offering of the Shares, including all documents incorporated therein by reference, filed with the Commission pursuant to General Instruction II.L of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the “U.S.
Appears in 1 contract
Sources: Underwriting Agreement (Aurinia Pharmaceuticals Inc.)
Base Prospectus. The preliminary prospectus supplement dated July 22March 10, 2020, 2014 relating to the offering of the SharesSecurities, including all documents incorporated therein by reference, filed with the Commission pursuant to General Instruction II.L 11.L of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the “U.S.a "U.
Appears in 1 contract
Sources: Underwriting Agreement (TEKMIRA PHARMACEUTICALS Corp)
Base Prospectus. The preliminary prospectus supplement dated July 22October 16, 2020, 2013 relating to the offering of the SharesSecurities, including all documents incorporated therein by reference, filed with the Commission pursuant to General Instruction II.L of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the a “U.S.
Appears in 1 contract
Sources: Underwriting Agreement (TEKMIRA PHARMACEUTICALS Corp)
Base Prospectus. The preliminary prospectus supplement dated July 22December 9, 20202019, relating to the offering of the Shares, including all documents incorporated therein by reference, filed with the Commission pursuant to General Instruction II.L of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the “U.S.
Appears in 1 contract
Sources: Underwriting Agreement (Aurinia Pharmaceuticals Inc.)
Base Prospectus. The preliminary prospectus supplement dated July 22March 25, 2020, 2013 relating to the offering of the Shares, including all documents incorporated therein by reference, filed with the Commission SEC pursuant to General Instruction II.L of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the a “U.S.
Appears in 1 contract
Base Prospectus. The preliminary prospectus supplement dated July 22April 2, 2020, 2012 relating to the offering of the SharesSecurities, including all documents incorporated therein by reference, filed with the Commission pursuant to General Instruction II.L of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the a “U.S.
Appears in 1 contract
Base Prospectus. The preliminary prospectus supplement dated July 22October 16, 2020, 2013 relating to the offering of the SharesSecurities, including all documents incorporated therein by reference, filed with the Commission pursuant to General Instruction II.L ILL of Form F-10 under the Securities Act, together with the U.S. Base Prospectus, is hereinafter called the “U.S.a "
Appears in 1 contract
Sources: Underwriting Agreement (TEKMIRA PHARMACEUTICALS Corp)